Alzamend Neuro, Inc. Common Stock
ALZNStock
$1.22−61.71%52W
Market Cap$4.64M
P/E—
Div yield—
Beta0.23
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-51.87%
Price vs S&P 500 (4W)-1.23%
VGM Score53.27
Market Capitalization$4.64M
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALZNAlzamend Neuro, Inc. Common Stock | — | — | C | $1.22 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Alzamend Neuro is an early-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases and psychiatric disorders, with a focus on Alzheimer's disease. Its pipeline consists of AL001, a patented lithium-based ionic cocrystal technology, and AL002, a cell-based therapeutic vaccine designed to restore immune response against Alzheimer's.